Skip to main content
. 2016 Nov 24;18:272. doi: 10.1186/s13075-016-1170-3

Fig. 3.

Fig. 3

Rates of Juvenile Disease Activity Score (JADAS)10 remission and minimal disease activity in patients taking etanercept, adalimumab or tocilizumab